



an Open Access Journal by MDPI

## Neuropathic Diseases: From Mechanisms to Novel Therapeutic Approaches

Guest Editors:

**Dr. Yu-Cheng Ho**

School of Medicine, College of  
Medicine, I-Shou University,  
Kaohsiung City 82445, Taiwan

**Dr. Ming Tatt Lee**

Faculty of Pharmaceutical  
Sciences, UCSI University, Kuala  
Lumpur, Malaysia

Deadline for manuscript  
submissions:

**15 May 2024**

### Message from the Guest Editors

Dear Colleagues,

Neuropathic pain is caused by lesions or degeneration of the somatosensory system and is a major public health issue in the world. Although the treatment for neuropathic pain remains a great challenge, progress has been made in identifying key molecules and their roles in pain modulation and processing. Thus, the identification of novel molecular and cellular targets for the development of effective and safe therapeutic strategies requires particular attention from the medical community.

In this Special Issue, original research articles and reviews are welcome. The purpose of this issue is to advance our understanding of novel neuropathic pain-related molecules and signaling pathways that can be used as therapeutic targets for the treatment of pain. Research areas may include (but not limited to) the following:

- Identification of potential therapeutic targets and pathophysiological mechanisms of neuropathic pain;
- Novel molecules, which are implicated in the pathophysiological changes in somatosensory system.

Dr. Yu-Cheng Ho  
Dr. Ming Tatt Lee  
*Guest Editors*



[mdpi.com/si/151870](https://mdpi.com/si/151870)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)